MAY 21, 2020 10:40 AM PDT

Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer

WRITTEN BY: Annie Lennon

Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repurpose antibody-based autoimmunity drugs to treat cancer. Turning on a simple molecular 'switch,' they were able to successfully use these drugs to treat cancer in preclinical trials.

CD40 is a molecule found on the surface of immune cells that is known to play a role in autoimmunity disorders and cancer. Overstimulation of the molecule increases the chance of the immune system attacking healthy cells. Meanwhile, under-stimulation allows cancerous tumor cells to sneak past the immune system and multiply. Due to its role in both diseases, CD40 is a drug target for both autoimmune and cancer treatments. 

Although drugs are currently under development to either activate or suppress CD40, until recently, they were developed in isolation of each other. But his may no longer need to be the case. Researchers have found a way to invert the function of CD40 by merely modifying the 'constant' domain of different antibody treatments. 

Using this inversion 'trick' in the antibody drugs, they were able to change drugs from being CD40 suppressors (for autoimmune disorders) to CD40 activators (for cancer). One, in particular, was able to stimulate the immune system to fight cancer more effectively in preclinical trials than the best CD40-targeting antibody currently in clinical trials.  

"Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure," said Professor Mark Cragg, senior author of the study. "Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future".

 

Sources: Medical Xpress, Cancer Cell

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 27, 2021
Immunology
Rethinking Immune Responses Involved in Skin Hypersensitivity
JUL 27, 2021
Rethinking Immune Responses Involved in Skin Hypersensitivity
A study by immunologists at the University of Copenhagen has revealed a never-before-seen immune pathway invol ...
JUL 22, 2021
Health & Medicine
High Stress and Self Medication: Variables of Teenage Cannabis Use and Mental Health
JUL 22, 2021
High Stress and Self Medication: Variables of Teenage Cannabis Use and Mental Health
It is theorized that young members of the LGB community are thought to be heavier cannabis users. This heavier, and pote ...
JUL 23, 2021
Cancer
New Drug Eradicates Breast Cancer Tumors in Days
JUL 23, 2021
New Drug Eradicates Breast Cancer Tumors in Days
A new drug can kill between 95 and 100% of cancer cells in mice with human estrogen-receptor-positive breast cancer. The ...
AUG 13, 2021
Drug Discovery & Development
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
AUG 13, 2021
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The stu ...
AUG 18, 2021
Cannabis Sciences
Cancer Patients Use Less Cannabis than General Public
AUG 18, 2021
Cancer Patients Use Less Cannabis than General Public
Despite increasing legalization for recreational cannabis across the US, cancer patients have largely abstained from usi ...
SEP 13, 2021
Genetics & Genomics
Moderna is Developing mRNA Vaccines to Rescue Different Protein Defects
SEP 13, 2021
Moderna is Developing mRNA Vaccines to Rescue Different Protein Defects
A genome contains instructions for making genes, and when an organism needs to produce proteins, it transcribes a gene s ...
Loading Comments...